Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
1996 1
1997 3
1998 1
1999 1
2000 1
2002 1
2004 2
2005 1
2011 1
2014 1
2016 1
2017 1
2018 2
2019 3
2020 1
2021 6
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Overcoming tumor resistance mechanisms in CAR-NK cell therapy.
Valeri A, García-Ortiz A, Castellano E, Córdoba L, Maroto-Martín E, Encinas J, Leivas A, Río P, Martínez-López J. Valeri A, et al. Among authors: leivas a. Front Immunol. 2022 Aug 3;13:953849. doi: 10.3389/fimmu.2022.953849. eCollection 2022. Front Immunol. 2022. PMID: 35990652 Free PMC article. Review.
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. Leivas A, et al. Blood Cancer J. 2021 Aug 14;11(8):146. doi: 10.1038/s41408-021-00537-w. Blood Cancer J. 2021. PMID: 34392311 Free PMC article.
The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach.
Ríos-Tamayo R, Puig N, Algarín M, García de Veas Silva JL, Barbosa N, Encinas C, Hernández JÁ, Alonso R, Campos ML, Rodríguez T, Leivas A, Olivares MJ, Sánchez MJ, Paiva B, Lahuerta JJ, Martínez-López J. Ríos-Tamayo R, et al. Among authors: leivas a. Diagnostics (Basel). 2021 Oct 30;11(11):2020. doi: 10.3390/diagnostics11112020. Diagnostics (Basel). 2021. PMID: 34829367 Free PMC article. Review.
NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells.
Ibáñez-Navarro M, Fernández A, Escudero A, Esteso G, Campos-Silva C, Navarro-Aguadero MÁ, Leivas A, Caracuel BR, Rodríguez-Antolín C, Ortiz A, Navarro-Zapata A, Mestre-Durán C, Izquierdo M, Balaguer-Pérez M, Ferreras C, Martínez-López J, Valés-Gómez M, Pérez-Martínez A, Fernández L. Ibáñez-Navarro M, et al. Among authors: leivas a. Front Immunol. 2023 Oct 18;14:1187665. doi: 10.3389/fimmu.2023.1187665. eCollection 2023. Front Immunol. 2023. PMID: 37928520 Free PMC article.
Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma.
Rodríguez-García A, Linares M, Morales ML, Allain-Maillet S, Mennesson N, Sanchez R, Alonso R, Leivas A, Pérez-Rivilla A, Bigot-Corbel E, Hermouet S, Martínez-López J. Rodríguez-García A, et al. Among authors: leivas a. Front Immunol. 2022 Jan 11;12:797209. doi: 10.3389/fimmu.2021.797209. eCollection 2021. Front Immunol. 2022. PMID: 35087522 Free PMC article.
Natural killer cells efficiently target multiple myeloma clonogenic tumor cells.
Leivas A, Risueño RM, Guzmán A, Sánchez-Vega L, Pérez M, Megías D, Fernández L, Alonso R, Pérez-Martínez A, Rapado I, Martínez-López J. Leivas A, et al. Cancer Immunol Immunother. 2021 Oct;70(10):2911-2924. doi: 10.1007/s00262-021-02901-y. Epub 2021 Mar 10. Cancer Immunol Immunother. 2021. PMID: 33693963 Free PMC article.
High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.
Castillo-Villalba J, Gil-Perotín S, Gasque-Rubio R, Cubas-Nuñez L, Carratalà-Boscà S, Alcalá C, Quintanilla-Bordás C, Pérez-Miralles F, Ferrer C, Cañada Martínez A, Tortosa J, Solís-Tarazona L, Campos L, Leivas A, Laíz Marro B, Casanova B. Castillo-Villalba J, et al. Among authors: leivas a. Front Immunol. 2022 Mar 7;13:827738. doi: 10.3389/fimmu.2022.827738. eCollection 2022. Front Immunol. 2022. PMID: 35330910 Free PMC article.
GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L, Fernández A, Mirones I, Escudero A, Cardoso L, Vela M, Lanzarot D, de Paz R, Leivas A, Gallardo M, Marcos A, Romero AB, Martínez-López J, Pérez-Martínez A. Fernández L, et al. Among authors: leivas a. Front Immunol. 2019 Oct 10;10:2361. doi: 10.3389/fimmu.2019.02361. eCollection 2019. Front Immunol. 2019. PMID: 31649672 Free PMC article.
MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia.
Morales ML, Arenas A, Ortiz-Ruiz A, Leivas A, Rapado I, Rodríguez-García A, Castro N, Zagorac I, Quintela-Fandino M, Gómez-López G, Gallardo M, Ayala R, Linares M, Martínez-López J. Morales ML, et al. Among authors: leivas a. Sci Rep. 2019 Dec 9;9(1):18630. doi: 10.1038/s41598-019-54901-9. Sci Rep. 2019. PMID: 31819100 Free PMC article.
Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits.
Fernández A, Pérez-Martínez A, Escudero A, Mirones I, González B, de Paz R, Matamala N, Clares L, Navarro A, Galán V, Martínez-Romera I, Martínez-López J, Leivas A, Valés-Gómez M, Ferreras C, Fernández L. Fernández A, et al. Among authors: leivas a. Leuk Lymphoma. 2022 Aug;63(8):1970-1974. doi: 10.1080/10428194.2022.2057490. Epub 2022 Apr 3. Leuk Lymphoma. 2022. PMID: 35369829 No abstract available.
35 results